Chapter 1. Research Background
1.1. Research Objectives
1.2. Market Definition
1.3. Research Scope
1.3.1. Market Segmentation by Drug Class
1.3.2. Market Segmentation by Route of Administration
1.3.3. Market Segmentation by Geography
1.3.4. Analysis Period
1.3.5. Market Data Reporting Unit
1.4. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By region
2.2.1.2. By industry participants
2.2.1.3. By company type
2.3. Market Size Estimation
2.4. Market Breakdown and Data Triangulation
2.5. Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1. Market Segmentation
4.1.1. Overview by Drug Class
4.1.1.1. Bronchodilators
4.1.1.2. Mast cell stabilizers
4.1.1.3. Leukotriene antagonists
4.1.1.4. Immunosuppressants
4.1.1.5. Combination therapies
4.1.2. Overview by Route of Administration
4.1.2.1. Oral
4.1.2.2. Inhaled
4.1.2.3. Others
4.2. Value Chain Analysis
4.3. Market Dynamics
4.3.1. Trends
4.3.2. Drivers
4.3.2.1. Impact analysis of drivers on market forecast
4.3.3. Restraints
4.3.3.1. Impact analysis of restraints on market forecast
4.3.4. Opportunities
4.4. Porter’s Five Forces Analysis
Chapter 5. Market Size and Forecast by Drug Class
5.1. Bronchodilators
5.2. Mast Cell Stabilizers
5.3. Leukotriene Antagonists
5.4. Immunosuppressants
5.5. Combination Therapies
Chapter 6. Market Size and Forecast by Route of Administration
6.1. Oral
6.2. Inhaled
6.3. Others
Chapter 7. Market Size and Forecast by Geography
7.1. North America Asthma Market
7.1.1. By Drug Class
7.1.2. By Route of Administration
7.1.3. By Country-The U.S and Others
7.2. Europe Asthma Market
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Country –Germany, Spain, France, Italy and Rest of Europe
7.3. Asia-Pacific Asthma Market
7.3.1. By Drug Class
7.3.2. By Route of Administration
7.3.3. By Country -China, Japan, India and Rest of Asia-Pacific
7.4. Latin America Asthma Market
7.4.1. By Drug Class
7.4.2. By Route of Administration
7.4.3. By Country -Brazil, Mexico and Rest of Latin America
7.5. Middle East and Africa (MEA) Asthma Market
7.5.1. By Drug Class
7.5.2. By Route of Administration
7.5.3. By Country -South Africa and Rest of MEA
Chapter 8. Competitive Landscape
8.1. Competitive Analysis of Key Players
8.2. Global Strategic Developments
Chapter 9. Company Profiles
9.1. GlaxoSmithKline plc
9.1.1. Business Overview
9.1.2. Product and Service Offerings
9.1.3. Key Financial Summary
9.1.4. Strategic Growth Plan
9.2. Merck & Co., Inc.
9.2.1. Business Overview
9.2.2. Product and Service Offerings
9.2.3. Key Financial Summary
9.2.4. Strategic Growth Plan
9.3. AstraZeneca plc
9.3.1. Business Overview
9.3.2. Product and Service Offerings
9.3.3. Key Financial Summary
9.3.4. Strategic Growth Plan
9.4. Novartia AG
9.4.1. Business Overview
9.4.2. Product and Service Offerings
9.4.3. Key Financial Summary
9.4.4. Strategic Growth Plan
9.5. F. Hoffmann La-Roche Ltd.
9.5.1. Business Overview
9.5.2. Product and Service Offerings
9.5.3. Key Financial Summary
9.5.4. Strategic Growth Plan
9.6. Teva Pharmaceutical Industries Ltd.
9.6.1. Business Overview
9.6.2. Product and Service Offerings
9.6.3. Key Financial Summary
9.6.4. Strategic Growth Plan
9.7. Boehringer Ingelheim GmbH
9.7.1. Business Overview
9.7.2. Product and Service Offerings
9.7.3. Key Financial Summary
9.7.4. Strategic Growth Plan
9.8. Sunovion Pharmaceuticals Inc.
9.8.1. Business Overview
9.8.2. Product and Service Offerings
9.8.3. Key Financial Summary
9.8.4. Strategic Growth Plan
9.9. Ono Pharmaceutical Co., Ltd.
9.9.1. Business Overview
9.9.2. Product and Service Offerings
9.9.3. Key Financial Summary
9.9.4. Strategic Growth Plan
9.10. Koninklijke Philips N.V.
9.10.1. Business Overview
9.10.2. Product and Service Offerings
9.10.3. Key Financial Summary
9.10.4. Strategic Growth Plan
*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.
Chapter 10. Appendix
10.1. Abbreviations
